Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,628
archived clinical trials in
Schizophrenia

Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia
A Randomized, Double-blind, Placebo-controlled, Cross-over, Single-dose Study to Evaluate the Effects of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia Including a One Week Multiple-dose Extension to Assess the Persistence of Observed Effects
Status: Archived
PAREXEL (California Clinical Trials Medical Group), 1560 Chevy Chase Drive, Suite 140,
mi
from
Glendale, CA
Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia
A Randomized, Double-blind, Placebo-controlled, Cross-over, Single-dose Study to Evaluate the Effects of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia Including a One Week Multiple-dose Extension to Assess the Persistence of Observed Effects
Status: Archived
Updated: 1/1/1970
PAREXEL (California Clinical Trials Medical Group), 1560 Chevy Chase Drive, Suite 140,
mi
from
Glendale, CA
Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia
A Randomized, Double-blind, Placebo-controlled, Cross-over, Single-dose Study to Evaluate the Effects of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia Including a One Week Multiple-dose Extension to Assess the Persistence of Observed Effects
Status: Archived
CRI Worldwide, LLC
mi
from
Philadelphia, PA
Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia
A Randomized, Double-blind, Placebo-controlled, Cross-over, Single-dose Study to Evaluate the Effects of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia Including a One Week Multiple-dose Extension to Assess the Persistence of Observed Effects
Status: Archived
Updated: 1/1/1970
CRI Worldwide, LLC
mi
from
Philadelphia, PA
Metformin for Weight Loss in Schizophrenia
Evaluation of the Efficacy of Metformin for Weight Loss and Metabolic Effects In Overweight Psychiatric Patients Treated With Antipsychotic Medication
Status: Archived
Manhattan Psychiatric Center
mi
from
New York, NY
Metformin for Weight Loss in Schizophrenia
Evaluation of the Efficacy of Metformin for Weight Loss and Metabolic Effects In Overweight Psychiatric Patients Treated With Antipsychotic Medication
Status: Archived
Updated: 1/1/1970
Manhattan Psychiatric Center
mi
from
New York, NY
fMRI Cholinergic Mechanisms in Schizophrenia
fMRI Cholinergic Mechanisms in Schizophrenia
Status: Archived
Veterans Affairs Medical Center - Dallas
mi
from
Dallas, TX
fMRI Cholinergic Mechanisms in Schizophrenia
fMRI Cholinergic Mechanisms in Schizophrenia
Status: Archived
Updated: 1/1/1970
Veterans Affairs Medical Center - Dallas
mi
from
Dallas, TX
A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder
A Randomized, Double-Blind, Placebo-Controlled, Parellel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder
Status: Archived
Clinical Trial Facility
mi
from
Santa Clara, CA
A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder
A Randomized, Double-Blind, Placebo-Controlled, Parellel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Santa Clara, CA
A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder
A Randomized, Double-Blind, Placebo-Controlled, Parellel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder
Status: Archived
Clinical Trial Facility
mi
from
Denver, CO
A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder
A Randomized, Double-Blind, Placebo-Controlled, Parellel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Denver, CO
A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder
A Randomized, Double-Blind, Placebo-Controlled, Parellel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder
Status: Archived
Clinical Trial Facility
mi
from
Celebration, FL
A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder
A Randomized, Double-Blind, Placebo-Controlled, Parellel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Celebration, FL
A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder
A Randomized, Double-Blind, Placebo-Controlled, Parellel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder
Status: Archived
Clinical Trial Facility
mi
from
Atlanta, GA
A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder
A Randomized, Double-Blind, Placebo-Controlled, Parellel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Atlanta, GA
A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder
A Randomized, Double-Blind, Placebo-Controlled, Parellel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder
Status: Archived
Clinical Trial Facility
mi
from
Centralia, IL
A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder
A Randomized, Double-Blind, Placebo-Controlled, Parellel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Centralia, IL
A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder
A Randomized, Double-Blind, Placebo-Controlled, Parellel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder
Status: Archived
Clinical Trial Facility
mi
from
Kansas City, KA
A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder
A Randomized, Double-Blind, Placebo-Controlled, Parellel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Kansas City, KA
A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder
A Randomized, Double-Blind, Placebo-Controlled, Parellel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder
Status: Archived
Clinical Trial Facility
mi
from
Jackson, MS
A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder
A Randomized, Double-Blind, Placebo-Controlled, Parellel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Jackson, MS
A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder
A Randomized, Double-Blind, Placebo-Controlled, Parellel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder
Status: Archived
Clinical Trial Facility
mi
from
St Louis, MO
A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder
A Randomized, Double-Blind, Placebo-Controlled, Parellel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
St Louis, MO
A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder
A Randomized, Double-Blind, Placebo-Controlled, Parellel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder
Status: Archived
Clinical Trial Facility
mi
from
Albany, NY
A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder
A Randomized, Double-Blind, Placebo-Controlled, Parellel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Albany, NY
A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder
A Randomized, Double-Blind, Placebo-Controlled, Parellel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder
Status: Archived
Clinical Trial Facility
mi
from
Philadelphia, PA
A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder
A Randomized, Double-Blind, Placebo-Controlled, Parellel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Philadelphia, PA
A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder
A Randomized, Double-Blind, Placebo-Controlled, Parellel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder
Status: Archived
Clinical Trial Facility
mi
from
Austin, TX
A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder
A Randomized, Double-Blind, Placebo-Controlled, Parellel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Austin, TX
A Study to Evaluate the Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder (Study P06522)
A Sequential Groups, Open Label, Rising Multiple Dose Study to Assess the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder
Status: Archived
Clinical Research Facility
mi
from
Atlanta, GA
A Study to Evaluate the Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder (Study P06522)
A Sequential Groups, Open Label, Rising Multiple Dose Study to Assess the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Atlanta, GA
A Study to Evaluate the Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder (Study P06522)
A Sequential Groups, Open Label, Rising Multiple Dose Study to Assess the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder
Status: Archived
Clinical Research Facility
mi
from
Houston, TX
A Study to Evaluate the Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder (Study P06522)
A Sequential Groups, Open Label, Rising Multiple Dose Study to Assess the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Houston, TX
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Birmingham Psychiatry Pharmaceutical Studies, Inc.
mi
from
Birmingham, AL
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
Birmingham Psychiatry Pharmaceutical Studies, Inc.
mi
from
Birmingham, AL
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Comprehensive NeuroScience
mi
from
Cerritos, CA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
Comprehensive NeuroScience
mi
from
Cerritos, CA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
ATP Clinical Research, Inc.
mi
from
Costa Mesa, CA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
ATP Clinical Research, Inc.
mi
from
Costa Mesa, CA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Collaborative Neuroscience Network
mi
from
Garden Grove, CA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
Collaborative Neuroscience Network
mi
from
Garden Grove, CA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Apostle Clinical Trials, Inc.
mi
from
Long Beach-Lakewood, CA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
Apostle Clinical Trials, Inc.
mi
from
Long Beach-Lakewood, CA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Pacific Health Systems
mi
from
National City, CA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
Pacific Health Systems
mi
from
National City, CA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Pacific Research Partners, LLC
mi
from
Oakland, CA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
Pacific Research Partners, LLC
mi
from
Oakland, CA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Excell Research, Inc.
mi
from
Oceanside, CA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
Excell Research, Inc.
mi
from
Oceanside, CA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
David Geffen School of Medicine, UCLA
mi
from
Los Angeles, CA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
David Geffen School of Medicine, UCLA
mi
from
Los Angeles, CA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Artemis Institiute for Clinical Research
mi
from
San Diego, CA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
Artemis Institiute for Clinical Research
mi
from
San Diego, CA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Affiliated Research Institute
mi
from
San Diego, CA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
Affiliated Research Institute
mi
from
San Diego, CA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
California Neuropsychopharmacology Clinical Research Institute (CNRI)
mi
from
San Diego, CA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
California Neuropsychopharmacology Clinical Research Institute (CNRI)
mi
from
San Diego, CA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Neuropsychiatric Research Center of Orange County
mi
from
Santa Ana, CA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
Neuropsychiatric Research Center of Orange County
mi
from
Santa Ana, CA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Viking Clinical Research
mi
from
Temecula, CA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
Viking Clinical Research
mi
from
Temecula, CA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Collaborative Neuroscience Network, INC
mi
from
Torrance, CA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
Collaborative Neuroscience Network, INC
mi
from
Torrance, CA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
The Hospital of Central Connecticut at New Britain General
mi
from
New Britain, CT
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
The Hospital of Central Connecticut at New Britain General
mi
from
New Britain, CT
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Comprenhensive Neuroscience
mi
from
Washington,
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
Comprenhensive Neuroscience
mi
from
Washington,
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Amit K. Vijapura MD & Associates
mi
from
Jacksonville, FL
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
Amit K. Vijapura MD & Associates
mi
from
Jacksonville, FL
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Scientific Clinical Research
mi
from
North Miami, FL
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
Scientific Clinical Research
mi
from
North Miami, FL
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Atlanta Center for Medical Research
mi
from
Atlanta, GA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
Atlanta Center for Medical Research
mi
from
Atlanta, GA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Comprehensive NeuroScience, Inc.
mi
from
Atlanta, GA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
Comprehensive NeuroScience, Inc.
mi
from
Atlanta, GA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Northwest Behavioral Research Center
mi
from
Roswell, GA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
Northwest Behavioral Research Center
mi
from
Roswell, GA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Carman Research
mi
from
Smyrna, GA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
Carman Research
mi
from
Smyrna, GA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Institute for Behavioral Medicine
mi
from
Smyrna, GA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
Institute for Behavioral Medicine
mi
from
Smyrna, GA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Alexian Brothers Center for Mental Health
mi
from
Arlington Heights, IL
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
Alexian Brothers Center for Mental Health
mi
from
Arlington Heights, IL
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Rush University Medical Center
mi
from
Chicago, IL
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
Rush University Medical Center
mi
from
Chicago, IL
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
University of Illinois College of Medicine
mi
from
Chicago, IL
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
University of Illinois College of Medicine
mi
from
Chicago, IL
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
AMR Baber Research Inc.
mi
from
Naperville, IL
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
AMR Baber Research Inc.
mi
from
Naperville, IL
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Midwest Center for Neurobehavioral Medicine
mi
from
Oakbrook Terrace, IL
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
Midwest Center for Neurobehavioral Medicine
mi
from
Oakbrook Terrace, IL
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Louisiana Clinical Research
mi
from
Shreveport, LA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
Louisiana Clinical Research
mi
from
Shreveport, LA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Neurobehavioral Medicine Group
mi
from
Bloomfield Hills, MI
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
Neurobehavioral Medicine Group
mi
from
Bloomfield Hills, MI
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Rochester Center for Behavioral Medicine
mi
from
Rochester Hills, MI
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
Rochester Center for Behavioral Medicine
mi
from
Rochester Hills, MI
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Precise Research Centers
mi
from
Flowood, MS
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
Precise Research Centers
mi
from
Flowood, MS